ArticleThe Journal of clinical investigation2026
Rheumatoid factor production is genetically and molecularly distinct from rheumatoid arthritis.
Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Why a positive rheumatoid factor test does not always mean rheumatoid arthritis.The Journal of clinical investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDRheumatoid factor (RF) autoantibodies are highly prevalent, yet the molecular determinants of RF development and its progression to rheumatoid arthritis (RA) remain poorly understood. Here, we define the genetic, phenotypic, and molecular architecture of RF and its progression to RA.METHODSA total of 469,036 UK Biobank participants with RF testing and 76 Allen Institute for Immunology-University of California, San Diego-University of Colorado Transition to Rheumatoid Arthritis (ALTRA) cohort individuals were studied. Phenome-wide association studies (PheWAS), GWAS, and proteome-wide association studies (PWAS) compared RF+ individuals who did not have autoimmune disease with RF- control individuals. Single-cell RNA-seq enabled pseudobulk differential expression and cytokine signature enrichment analyses.RESULTSRF seroprevalence was 9.3% and longitudinally stable in 94.5% of individuals. PheWAS identified 48 significant associations, led by chronic viral hepatitis (OR 4.8), hypersensitivity pneumonitis (OR 3.6), bronchiectasis (OR 1.9), and COPD (OR 1.4). GWAS of 24,216 RF+ individuals revealed 29 independent loci; the strongest signal was in the extended HLA region (OR 1.45, P = 5.4 × 10-221). Non-HLA loci converged on B cell homeostasis genes (ETS1, BACH2, PAX5, TNFRSF13B, FCGR2A). RF+ individuals did not carry elevated RA polygenic risk. Proteomics profiling identified 153 differentially abundant proteins enriched for humoral immunity and IFN-induced chemokines, with 79% showing dose response relationships across titers. Progression to RA involved a shift toward activating tissue-damaging inflammatory pathways rather than amplification of the RF signature. Single-cell transcriptomics of RF+ individuals without RA localized dysregulation to memory B cells, with downregulation of inhibitory genes (FCGR2B, BACH2, FOXP1) and upregulation of activation markers.CONCLUSIONRF production is governed by HLA class II and B cell regulatory loci, associated with mucosal inflammation, and genetically and molecularly distinct from RA.FUNDINGThis study was supported by the Rheumatoid Arthritis Research Program Grant from the Arthritis Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.